Bristol-Myers Squibb Foundation awards $1.6 million in grants

Bristol-Myers SquibbThe Bristol-Myers Squibb Foundation announced $1.6 million in grants to four health care institutions in India that will help improve diabetes education, prevention and care and increase health care worker capacity in rural and tribal areas and among the urban poor.

The prevalence of diabetes in India has grown roughly four-fold since the early 1970s - from about 2 percent of the population in 1972 to 8.3 percent today - due to factors ranging from genetic predisposition to lifestyle and dietary changes. The International Diabetes Foundation (IDF) reports that 61.26 million people in India are diagnosed with type 2 diabetes, ranking India second only to China in total cases and third behind the United States (10.9 percent) and China (9.3 percent) in terms of prevalence. By 2030, India will have 101.2 million people with type 2 diabetes, IDF projects.

"Stemming the rising tide of type 2 diabetes in India will require a concerted and sustained effort at the community level to ensure adults have access to the education, preventive measures and care they need to effectively self-manage their disease," said John Damonti, president, Bristol-Myers Squibb Foundation. "The grants we are making today through our Together on Diabetes™ initiative will test new ideas about how diabetes control efforts can be best designed and implemented to help adults in a variety of settings."

The Foundation has employed a similar capacity-building approach with its 10-year-old Delivering Hope™ initiative to address hepatitis B and C in Asia, and its ongoing work to address unmet medical needs, reduce health disparities and build community health care capacity was recognized in late July by CMO Asia with an Asia's Best CSR Practices Award in the Concern for Health category.

The following organizations will receive Together on Diabetes™ grants:

  • Mamta Health Institute for Mother and Child, a national organization based in New Delhi and operating in 14 Indian states, will receive US $706,995 over three years to pilot a study to determine the feasibility of involving India’s lay community health workers (Accredited Social Health Activists) and integrating various systems of medicine including modern and AYUSH, to prevent and control non-communicable diseases, especially type 2 diabetes.
  • All India Institute of Diabetes and Research in Naranpura and Swasthya Diabetes Hospital in Ahmedabad will receive US $465,685 over two years to develop and test a three-setting model to improve access to diabetes education, prevention and care for the poor in rural, tribal and urban settings.
  • Sanjivani Health and Relief Committee in Ahmedabad will receive US $426,374 over four years to conduct a household-by-household study in 348 villages to identify type 2 diabetes and ensure early diagnosis of undetected diabetes among those with pre-diabetes or at high risk of developing diabetes. The study also will determine the prevalence of type 2 diabetes and related complications among the rural poor.

About Together on Diabetes™
Together on Diabetes™ brings together some of the world's most respected and influential health care organizations and academic institutions to develop effective, comprehensive solutions that integrate public health, health care services and supportive community supportive services to improve health outcomes and reduce disease burden.

Since its launch in November 2010, Together on Diabetes™ has awarded $32.57 million in grants to 17 organizations working in 23 states and the District of Columbia in the United States, $1.23 million to two organizations in China and $1.6 million to four organizations in India. The total commitment is $115 million through 2014.

About the Bristol-Myers Squibb Foundation
The Bristol-Myers Squibb Foundation is an independent 501(c)(3) charitable organization whose mission is to reduce health disparities and improve health outcomes around the world for patients disproportionately affected by serious diseases.

Most Popular Now

Top 20 breaking World Pharma News of 2017

We are proud to announce the top 20 most popular breaking World Pharma News from 2017. Have a wonderful 2018 new(s) year filled with health, happiness, and spectacular su...

Novartis advances head-to-head superiority trials …

Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondyl...

Diabetes drug 'significantly reverses memory loss…

A drug developed for diabetes could be used to treat Alzheimer's after scientists found it "significantly reversed memory loss" in mice through a triple method of action...

Sandoz regulatory submission for proposed biosimil…

Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics Licen...

Zika remains a research and public health challeng…

Since 2016, when Zika was declared by the World Health Organization as a public health emergency of international concern, the virus has become established in more than 8...

Try exercise to improve memory, thinking

For patients with mild cognitive impairment, don't be surprised if your health care provider prescribes exercise rather than medication. A new guideline for medical pract...

New research paper shows that AstraZeneca has achi…

In a research paper published today by Nature Reviews Drug Discovery(1), AstraZeneca's IMED Biotech Unit documents a more than four-fold improvement in R&D productivity f...

Dirt-dwelling microbe produces potential anti-mela…

A type of soil-dwelling bacterium produces molecules that induce death in melanoma cells, research at Oregon State University shows. The molecule is a secondary metabolit...

Novartis Kisqali® received FDA Breakthrough Therap…

Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pr...

FDA approves first treatment for breast cancer wit…

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast can...

Berry gives boost to cervical cancer therapy

According to the Centers for Disease Control and Prevention, approximately 12,000 women in the United States are diagnosed with cervical cancer each year. One of the most...

Novartis appoints Elizabeth Barrett as Oncology He…

Novartis announced today that Elizabeth (Liz) Barrett, currently Global President Oncology at Pfizer, Inc., has been appointed CEO Novartis Oncology and a member of the E...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]